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ABSTRACT
Regulation of protein synthesis makes a major contribution to post-
transcriptional control pathways. During disease, or under stress, cells
initiate processes to reprogramme protein synthesis and thus
orchestrate the appropriate cellular response. Recent data show that
the elongation stage of protein synthesis is a key regulatory node for
translational control in health and disease. There is a complex set of
factors that individually affect the overall rate of elongation and, for the
most part, these influence either transfer RNA (tRNA)- and eukaryotic
elongation factor 1A (eEF1A)-dependent codon decoding, and/or
elongation factor 2 (eEF2)-dependent ribosome translocation along
themRNA.Decoding speeds depend on the relative abundance of each
tRNA, the cognate:near-cognate tRNA ratios and the degree of tRNA
modification, whereas eEF2-dependent ribosome translocation is
negatively regulated by phosphorylation on threonine-56 by eEF2
kinase. Additional factors that contribute to the control of the elongation
rate include epigenetic modification of the mRNA, coding sequence
variation and the expression of eIF5A, which stimulates peptide bond
formation between proline residues. Importantly, dysregulation of
elongation control is central to disease mechanisms in both
tumorigenesis and neurodegeneration, making the individual key
steps in this process attractive therapeutic targets. Here, we discuss
the relative contribution of individual components of the translational
apparatus (e.g. tRNAs, elongation factors and their modifiers) to the
overall control of translation elongation and how their dysregulation
contributes towards disease processes.
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Introduction
Protein synthesis can be considered a three-stage process of initiation,
elongation and termination (Fig. 1). Data from a number of teams
have shown that the elongation stage is highly regulated, which is
perhaps unsurprising given that this step of mRNA translation
consumes almost all the energy utilised during protein synthesis
(Proud, 2015). However, compared to regulation of the initiation of
translation, elongation control has been much less studied.
Understanding the regulation of translation elongation is essential,
however, since it is now well established that dysregulation of this
process contributes to disease, e.g. cancers and neurodegeneration
(Faller et al., 2015; Jan et al., 2018; Beckelman et al., 2019).
In the elongation phase, the mRNA is decoded by the ribosome in
a process that requires selection of each aminoacyl-transfer RNA
(aa-tRNA), which is dictated by the mRNA codon in the ribosome
acceptor (A) site, peptide bond formation and movement of both
tRNAs and the mRNA through the ribosome (Voorhees and
Ramakrishnan, 2013) (Fig. 2). A new amino acid is incorporated
into a nascent peptide at a rate of approximately one every sixth of a
second (Voorhees and Ramakrishnan, 2013; Choi et al., 2018). The
first step of this process requires guanosine triphosphate (GTP)-
bound eukaryotic elongation factor 1A (eEF1A) to recruit an
aa-tRNA to the aminoacyl (A) site, which has an anticodon loop
cognate to the codon sequence of the mRNA (Choi et al., 2018). The
anticodon of this sampling tRNA does not initially base-pair with
the A-site codon. Instead, the tRNA dynamically remodels to
generate a codon-anticodon helix (Voorhees and Ramakrishnan,
2013), which stabilises the binding of the tRNA-eEF1A-GTP
complex to the ribosome A site (Rodnina et al., 2005). This helical
structure is energetically favourable for cognate or correct pairing,
and so discriminates between the non-cognate or unpaired and
single mismatched or near-cognate species (Choi et al., 2018). This
is important for the accuracy of decoding since it provides a
mechanism to reject a non-cognate tRNA that carries an
inappropriate amino acid (Plant et al., 2007). The pairing of the
tRNA and codon induces GTP hydrolysis by eEF1A, which is then
evicted from the A site. In parallel with this process, the ribosome
undergoes a conformational change that stimulates contact between
the 3′ end of the aa-tRNA in the A site and the tRNA carrying the
polypeptide chain in the peptidyl (P) site. The shift in position of the
two tRNAs [A to the P site and P to the exit (E) site] results in
ribosome-catalysed peptide bond formation and the transfer of the
polypeptide to the aa-tRNA, thus extending the polypeptide by one
amino acid (Moazed and Noller, 1989). The second stage of the
elongation cycle requires a GTPase, eukaryotic elongation factor 2
(eEF2), which enters the A-site and, through the hydrolysis of GTP,
induces a change in the ribosome conformation. This stimulates
ribosome translocation to allow the next aa-tRNA to enter the A-site
(Voorhees and Ramakrishnan, 2013; Choi et al., 2018), thus starting
a new cycle of elongation (Fig. 2). In this Review, we discuss how
the process of elongation is controlled, the relative contributions of
the individual components to this process, how they are in turn
regulated and how their dysregulation is associated with disease,
particularly cancers and neurodegeneration.
Control of tRNA-dependent decoding and its role in disease
A number of factors influence the rate at which elongation proceeds.
As discussed in detail below, decoding speeds are affected by the
relative abundance of each tRNA, the cognate:near-cognate tRNA
ratios (Sabi and Tuller, 2014; Fluitt et al., 2007; Tarrant and Von
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Der Haar, 2014), the extent of tRNA modification [particularly at
the uridine-34 (U34) wobble position] and the degree of tRNA
aminoacylation (Rezgui et al., 2013; Ranjan and Rodnina, 2017).
Elongation rates also depend on the activity of eEF2, which, as
discussed above, is required for ribosome translocation, and which
is negatively regulated by phosphorylation on threonine-56 (T56)
(Ryazanov and Davydova, 1989; Proud, 2015). Additional factors
that also contribute to the control of the elongation rate include
epigenetic modification of the mRNA coding sequence (Hanson
et al., 2018; Presnyak et al., 2015; Radhakrishnan et al., 2016) and
the expression levels of proteins with a role in elongation. This
includes eukaryotic translation initiation factor 5A (eIF5A), which
is required to stimulate peptide bond formation between proline
residues, whose rigid structures would otherwise impact negatively
on the elongation process (reviewed in Dever et al., 2014).
tRNA abundance
tRNA abundance is crucial for cell homeostasis. Functional tRNA
pool availability can be controlled at the level of transcription,
maturation, modification and charging. The human genome contains
∼500 tRNA genes, of which ∼300 are expressed (Chan and Lowe,
2016; Schimmel, 2018). As the genetic code is degenerate, each
amino acid can be encoded by two, four or six synonymous three-
nucleotide codons (with the exception of methionine and
tryptophan). Synonymous codons encoding the same amino acid
are used unevenly within a transcriptome, in a mechanism conserved
across organisms and termed ‘codon usage bias’ (Spencer et al.,
2012). Importantly, tRNA genes show differential tissue expression
(Dittmar et al., 2006; Gingold et al., 2014), which mirrors codon
usage bias. In this case, synonymous codons are over- or under-
represented in relation to the mRNAs that encode tissue-specific
proteins, which in turn control the expression levels of such proteins.
Thus, large relative differences in protein expression are achieved
when using luciferase variants that have been codon optimised,
according to the tRNA abundance in specific mammalian cell lines
(Xie et al., 2018). Moreover, in addition to tissue-specific differences
in tRNA expression levels, two distinct tRNA expression profiles
have been observed that correspond to pro-proliferation or pro-
differentiation codon usage signatures (Gingold and Pilpel, 2011;
Gingold et al., 2014). Taken together, these data indicate that tRNA
expression is tightly linked to cell-type-specific mRNA expression.
This is particularly the case in tumour-derived cells. While cancer
cells require elevated levels of tRNAs to respond to increased protein
synthesis rates (Pavon-Eternod et al., 2009; Zhou et al., 2009), the
data demonstrate that they also selectively reprogramme the tRNA
expression profile to favour codon usage required by a subset of
cancer-related genes (Gingold et al., 2014). This enhances their
translation and, in turn, promotes metastasis (Pavon-Eternod et al.,
2009; Goodarzi et al., 2015). For example, genetically engineered
overexpression of the initiator methionine tRNA in the mouse
promotes angiogenesis in tumour-associated fibroblasts and
metastasis of melanoma tumour cells (Clarke et al., 2016; Birch
et al., 2016). In contrast, mouse models have also shown that increased
bulk tRNA synthesis driven by overexpression of the RNApolymerase
III subunit Brf1 had little effect in a model of pancreatic tumorigenesis
(Liko et al., 2019), suggesting that specific tRNA reprogramming may
play a greater role than total tRNA expression levels in driving this
cancer. However, Brf1 overexpression in a mouse model of prostate
cancer accelerates the disease, indicating that increases in tRNA
expression may promote certain tumours, although it is possible that
this phenotype is driven by upregulation of specific tRNAs (Loveridge
et al., 2019). Importantly, the tRNAs induced in cancer cells favour a
pro-proliferative programme and their upregulation is associated with a
worse prognosis (Gingold et al., 2014; Hernandez-Alias et al., 2019).
tRNA wobble position and decoding
Certain codons can be decoded not only by cognate, but also by
near-cognate tRNAs. This flexibility is achieved via a mismatch
between the third base of the codon and the first base of the
anticodon, the ‘wobble’ position (Plant et al., 2007). In the human
genome, 14 tRNA anti-codons are decoded via wobble base-pairing
(Chan and Lowe, 2016), and some of these wobble-decoded codons
are decoded more slowly than the synonymous Watson-Crick-
decoded codons, due to a higher probability of incorrect rejection of
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Fig. 1. A schematic to represent the three-stage process of mRNA translation. Translation initiation involves the assembly of elongation-competent
ribosomes [shown in green and containing three tRNA-binding sites called the aminoacyl (A), peptidyl (P) and exit (E) sites] in which an initiator Met-tRNA base-
pairs with the initiation codon in the ribosomal P site. In general, initiation of translation is controlled by the bioavailability of eukaryotic initiation factors, RNA-
binding proteins that aid the recruitment of the mRNA to the ribosome and RNA regulatory motifs. Elongation rates are regulated by the availability of tRNAs, the
codon sequence of themessage, themodifications to the coding sequence and the activity of eEF2, with somemessages additionally requiring eIF5A. Met-tRNA,
methionine transfer RNA; m7G, 7-methylguanosine; 40s, small ribosomal subunit; 60s, large ribosomal subunit; 80s, ribosome.
2
REVIEW Disease Models & Mechanisms (2020) 13, dmm043208. doi:10.1242/dmm.043208
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
wobble-decoding tRNAs by the ribosome (Kothe and Rodnina,
2007). In agreement with this, ribosome occupancy times obtained
from foot-printing data using human cell lines shows increased
ribosome occupancy at wobble codons (Richter and Coller, 2015;
Stadler and Fire, 2011).
There are ∼100 different post-transcriptional modifications of
RNAs and the majority of these occur on tRNAs (Fig. 3). On average,
there are 13 modifications per tRNA molecule, although this varies,
e.g. tRNAHis is less modified, whereas tRNATyr is possibly the most
modified tRNA (El Yacoubi et al., 2012; de Crécy-Lagard et al.,
2019). Such modifications are an essential part of the maturation
process to generate functional tRNA molecules (El Yacoubi et al.,
2012; de Crécy-Lagard et al., 2019). They are crucial to the stability,
folding and decoding properties of tRNAs and in some cases regulate
tRNA charging, e.g. binding to aminoacyl-tRNA synthetases
(ARSs), the enzymes responsible for charging amino acids to their
cognate tRNAs (Schimmel, 2018; de Crécy-Lagard et al., 2019).
Modifications in the anticodon loop mainly affect decoding and
translational efficiency. Of particular importance is U34 of the tRNA
anticodon, which base-pairs with the wobble position of the codon
aa-tRNA
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Fig. 2. A schematic to represent the process of elongation. The four basic steps are shown. The ribosome contains three tRNA-binding sites: the aminoacyl
(A), peptidyl (P) and exit (E) sites. In the first step of peptide elongation, the tRNA, which is in a complex with eIF1 and GTP and contains the cognate anticodon to
the mRNA coding sequence, enters the A site. Recognition of the tRNA leads to the hydrolysis of GTP and eviction of eEF1 from the A site. In parallel, the
deacylated tRNA in the E site is ejected. The A site and the P site tRNAs interact, which allows ribosome-catalysed peptide bond formation to take place. This
involves the transfer of the polypeptide to the aa-tRNA, thus extending the nascent polypeptide by one amino acid. eIF5A allosterically assists in the formation of
certain peptide bonds, e.g. proline-proline. eEF2 then enters the A site and, through the hydrolysis of GTP, induces a change in the ribosome conformation and
stimulates translocation. The ribosome is then in a correct conformation to accept the next aa-tRNA and commence another cycle of elongation.
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and displays a wide variety of chemical modifications essential for
near-cognate binding (Phizicky and Hopper, 2010; Grosjean and
Westhof, 2016). This position is frequently modified in tRNAs that
decode split codon-box amino acids, in which the A- and G-ending
codons encode a different amino acid than the U- and C-ending
codons (Phizicky and Hopper, 2010; Grosjean and Westhof, 2016).
An in vitro study showed that U34 modifications in tRNALys(UUU)
and in tRNAGln(UUG) increased the affinity of the tRNA to its cognate
codon in the A site of the ribosome (Rezgui et al., 2013; Ranjan and
Rodnina, 2017) and therefore allowed faster translation. In addition,
many human tRNAs that have an A at the wobble base have a
modification from A to I (inosine), which allows base pairing from
A34-U to I34-U, I34-C or, in some cases, even to I34-A, increasing
the encoding capacity of the modified tRNAs (Novoa et al., 2012;
Pan, 2018).
Enzymes that catalyse U34 modifications have been implicated in
cancer and neurological diseases (Close et al., 2018). For example,
the Elongator complex is required for a subset of tRNAmodifications
at U34 to promote efficient decoding of G- and A-ending codons. It
comprises six functionally essential subunits, which include
Elongator complex protein 1 (ELP1; also known as IKAP and
IKBKAP) and the enzymatic component Elongator complex
protein 3 (ELP3) (Huang et al., 2005; Johansson et al., 2008).
Mutations in Elongator complex components have been associated
with various neurological diseases, including familial dysautonomia
(Karlsborn et al., 2014; Dalwadi and Yip, 2018). In this condition,
mutations in ELP1 reduce neuronal expression of full-length ELP1
protein and decrease U34 modification (Karlsborn et al., 2014;
Anderson et al., 2001; Slaugenhaupt et al., 2001; Dong et al., 2002;
Cuajungco et al., 2003; Yoshida et al., 2015). Consequently, this
results in a decoding deficiency, codon-specific ribosome pausing
and frameshifting, leading to the accumulation of misfolded proteins
(Rezgui et al., 2013; Tükenmez et al., 2015; Klassen et al., 2017;
Nedialkova and Leidel, 2015). In mice, this activates the PKR-
like endoplasmic reticulum (ER) kinase (PERK) pathway within the
unfolded protein response, a cellular response to restore ER
homeostasis in response to protein misfolding (recently reviewed in
Pizzinga et al., 2019), which interferes with the differentiation of
cortical progenitors and neurogenesis in the developing cortex by
promoting the generation of intermediate progenitors (Laguesse et al.,
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Fig. 3. Schematic representation of human tRNA. Residues with post-transcriptional modifications associated with human diseases are shown in green and the
wobble base (34) is shown in orange. The annotations explain the disease-associated tRNAmodification with the known protein(s) required for the tRNAmodifications
shown in brackets (de Crécy-Lagard et al., 2019): A, adenosine; C, cytidine; Cm, 2′-O-methylcytidine; cm5U, 5-carboxymethyl uridine; D, dihydrouridine; f5C,
5-formylcytidine; G, guanosine; Gm, 2′-O-methylguanosine; I, inosine; i6A, N6-isopentenyladenosine; m1, 1-methyl; m22G, N(2),N(2)-dimethylguanosine; m3,
3-methyl; m5, 5-methyl; m7, 7-methyl; mcm5s2U, 5-methoxycarbonylmethyl-2-thiouridine; mcm5U, 5-methoxycarbonylmethyluridine; ms2t6A, 2-methylthio-N(6)-
threonylcarbamoyladenosine; ncm5U, 5-carbamoylmethyluridine;Q, queosine; s2U, 2-thiouridine; t6A, N(6)-threonylcarbamoyladenosine; U, uridine; yW,wybutosine;
Ψ, pseudouridine; τm5U, 5-taurinomethyluridine; τm5s2U, 5-taurinomethyl-2-thiouridine.
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2015; Rezgui et al., 2013). The changes in decoding efficiency might
also drive an alternative translational programme that favours specific
codon subsets that perpetuate the disease state (Rezgui et al., 2013;
Fernández-Vázquez et al., 2013; Kapur and Ackerman, 2018). Thus,
Elongator-dependent tRNA modification plays critical roles in
defining the balance between proliferation and differentiation in
developing neural tissues, disruption of which is likely to play a
causal role in the pathogenesis of various neurological diseases
(Laguesse et al., 2015).
Elongator-dependent tRNA modifications are also dysregulated
in cancers with elevated ELP3 expression, such as WNT-dependent
colon cancer, breast cancer and BRAFV600E melanoma. In these
cancers, ELP3-mediated tRNA modification directs a codon-
specific translational programme. This promotes efficient
translation of transcripts that encode critical effectors of the
oncogenic state, such as SRY-box transcription factor 9 (Sox9) in
colon cancer, DEK in breast cancer and hypoxia-inducible factor
1-alpha (HIF1α) in BRAFV600E melanoma, to drive tumour
initiation, survival, metastasis and drug resistance (Ladang et al.,
2015; Delaunay et al., 2016; Rapino et al., 2018). In contrast, low
ELP3 expression is reportedly a factor of poor prognosis for
endometrioid adenocarcinoma (Wang et al., 2012). Hence, the role
of Elongator-dependent tRNA modifications in cancer appear to be
context dependent, but represent a promising opportunity for
therapeutic intervention in some neoplastic diseases.
tRNA aminoacylation
In order for a tRNA to be functional, it must first be charged with its
corresponding amino acid at its 3′ end by the appropriate ARS.
Reports suggest that >80% of tRNA isodecoders, which share a
common anticodon, but differ elsewhere in their sequence, in
human cells are charged, with the exception of tRNASer and
tRNAThr isodecoders, which are charged between 60% and 80%
(Evans et al., 2017). Aminoacylation controls the distribution of
charged tRNAs in the cell and therefore defects in this process can
cause highly abundant tRNAs to become functionally limited.
Consequently, mutations in genes that encode ARSs have been
associated with an array of human diseases, including neurological
disorders, with recessive and dominant phenotypes (Meyer-
Schuman and Antonellis, 2017). Indeed, neurons are particularly
vulnerable to translation elongation defects and the consequent
proteostatic disruption due to the specialised translational burden
required to facilitate synaptic plasticity and high metabolic activity
and restricted ability to dilute misfolded proteins through cell
division (Kapur et al., 2017; March et al., 2019). While mutations in
mitochondrial ARS genes predominantly affect tissues with high
metabolic activity such as the central nervous system, autosomal
recessive mutations in cytoplasmic ARS genes typically affect a
wider range of tissues, which usually include a neurological
component (Meyer-Schuman and Antonellis, 2017). In contrast, a
smaller number of ARS genes have been implicated in dominant
neuropathic disorders with a limited phenotypic range, most notably
Charcot-Marie-Tooth (CMT) disease (Meyer-Schuman and
Antonellis, 2017).
Recessive ARS mutant-associated disease pathogenesis is likely
caused by reductions in ARS protein levels and activity, resulting in
deficient charging of specific tRNAs, which could directly cause
ribosome stalling or frame shifting (Meyer-Schuman and
Antonellis, 2017; Zhang et al., 2010). Intriguingly, some ARS
mutations result in tissue-specific phenotypes, which might either
indicate that mutations in a specific ARS could modulate the
translation of cell-type-specific transcripts in a codon-dependent
manner or expose tissue-specific deficiencies in active tRNA pools
(Meyer-Schuman and Antonellis, 2017; Puffenberger et al., 2012).
Abnormal expression levels of different ARS genes have also been
reported in several cancers, but their pathogenic role has thus far
only been linked to non-canonical activities, such as signalling in
oncogenic pathways (Kushner et al., 1976; Scandurro et al., 2001;
Wasenius et al., 2003; Park et al., 2005; Tzima and Schimmel, 2006;
Vellaichamy et al., 2009; Kim et al., 2011; Kim et al., 2012).
In contrast, the pathogenesis of dominant ARS mutant disease is
possibly dictated by a dominant-negative mechanism whereby
levels of charged tRNA are depleted below a haploinsufficient state
through oligomerisation of a subfunctional ARS protein with wild-
type subunits (Malissovas et al., 2016). An alternative dominant
toxic gain-of-function effect for mutant glycine(G)ARS has
been proposed, perturbing neuronal signalling via interactions
with neuropilin-1 (NRP1) and neurotrophic receptor tyrosine kinase
1/2/3 (NTRK1/2/3; also known as TrkA/B/C) (He et al., 2015;
Sleigh et al., 2017). However, it is not clear whether either of these
potential mechanisms apply to all neuropathy-associated ARS
mutations, and research into a unifying mechanism of ARS-
mediated disease pathology remains ongoing (Meyer-Schuman and
Antonellis, 2017; Yao and Fox, 2013).
Control of elongation by eEF2K and eEF2, and disease status
Phosphorylation of eEF2 on threonine-56 inhibits its activity by
physically blocking entry into the A site, thereby reducing ribosome
translocation and the elongation rate (Proud, 2015). The enzyme
required for this phosphorylation is eEF2 kinase (eEF2K; a calcium/
calmodulin-dependent member of the α-kinase group). eEF2K,
which appears to be non-essential under physiological conditions, is
activated following nutrient and energy depletion to slow down the
rate of elongation (Proud, 2015). Interestingly, while eEF2K
knockout protected mice from a lethal dose of whole-body
ionizing radiation at 8 Gy by reducing apoptosis in the
gastrointestinal tract, it was not protective at 20 Gy, which causes
severe damage to the gastrointestinal tract and increases mitotic cell
death in small intestinal stem cells (Liao et al., 2016). Taken
together, these data suggest that eEF2K provides a protective
strategy in time of cells stress, but that this effect is cell-type
dependent. This is an important point when considering whether
eEF2K may be a useful target in the treatment of disease.
eEF2K in tumorigenesis
The role of eEF2K in cancer development has been studied
extensively; however, there is no current consensus as to whether
eEF2K is beneficial or detrimental to cancer cell survival. This has
led to the hypothesis that eEF2K could act as a ‘double-edged
sword’, with cancer-cell-type-specific functions (Liu and Proud,
2016). This is exemplified by data that correlate either high or low
eEF2K expression with improved patient prognosis (Table 1).
The promotion of cancer cell survival by eEF2K has been linked
to nutrient management in rapidly proliferating solid tumours,
where, due to the poor vascular structure, cancer cells have to adapt
to prolonged nutrient deprivation. Thus, inhibition of elongation
via eEF2K, and therefore energy conservation, enhanced the
survival of oncogene-transformed fibroblasts (Leprivier et al.,
2013). Moreover, similar data were obtained in an orthotopic model
of breast cancer using RNA interference (RNAi) suppression of
eEF2K (Tekedereli et al., 2012), and by pharmacological inhibition
of eEF2K in triple-negative murine breast cancer cells (Liu et al.,
2014). Importantly, these studies are supported by clinical data
showing a negative correlation between eEF2K expression and
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patient prognosis in medulloblastoma, glioblastoma multiforme
(Leprivier et al., 2013) and breast cancer (Table 1).
eEF2K is also required to maintain energy production during
acidosis and hypoxia, when it significantly reduces ATP levels and
induces cancer cell death (Xie et al., 2015). Similarly, eEF2K
knockdown was shown to generate acute sensitivity to oxidative
stress following suppression of the tumour suppressor p53
homologue TAp73 (Marini et al., 2018). Loss of TAp73 leads to a
remarkable eEF2K-dependent translation elongation blockade,
resulting in sensitivity to oxidative stress due to impaired
translation of mitochondrial proteins (Marini et al., 2018). Thus,
eEF2K acts downstream of TAp73 to allow translational
reprogramming and adaptation to oxidative stress, thereby
enhancing cancer cell survival. Additionally, eEF2K may actively
participate in rerouting metabolic pathways in cancer. eEF2K
maintains the expression of the pyruvate kinase isoform PK-M2
(also known as PKM), which promotes the switch to Warburg
metabolism in cancer cells (Cheng et al., 2016). However, it remains
to be determined how important the regulation of PK-M2 is to the
eEF2K-dependent response to nutrient deprivation or stress.
eEF2K is also important for cancer cell migration and metastasis.
A recent study that focused on the migratory andmetastatic potential
of cancer cells showed that knockdown or chemical inhibition of
eEF2K led to reduced integrin expression and decreased migration
and invasion both in vitro and in vivo (Xie et al., 2018). These data
are supported by previous studies in which inhibition or genetic
ablation of eEF2K suppressed cancer cell migration and invasion
(Bayraktar et al., 2017; Zhu et al., 2017).
Suppression of eEF2K can also promote tumorigenesis, with a
dramatic increase in cell proliferation driven by the elevated
elongation speed. In a mouse model of intestinal cancer driven by
loss of the adenomatous polyposis coli (Apc) gene, activation of
mechanistic target of rapamycin complex 1 (mTORC1) drives
increased translational elongation; however, this can be successfully
targeted with rapamycin to inhibit intestinal tumorigenesis (Faller
et al., 2015). The pharmacological targeting of mTORC1 required
functional eEF2K, suggesting that mTORC1 promotes intestinal
cancer by repressing eEF2K. Thus, low eEF2K activity is required
for rapid proliferation, which is consistent with low eEF2K
correlating with poor survival in colorectal cancer patients (Ng
et al., 2019).
In addition, there are data to suggest that the benefits of low
eEF2K activity in cancer may not be limited to colorectal cancer. In
tumour-derived cell lines, including HeLa, MCF7 and A549, as
well as RasV12-transformed mouse embryonic fibroblast (MEF)
lines, the anti-viral drug nelfinavir was shown to activate
eEF2K independently of mTORC1 inhibition or 5′ adenosine
monophosphate-activated protein kinase (AMPK), leading to the
phosphorylation of eEF2, decreased protein synthesis and increased
cancer cell death (De Gassart et al., 2016). eEF2K was required for
all nelfinavir-mediated anti-tumour activity, indicating suppression
of elongation to be the drug’s mechanism of action.
Collectively, studies of eEF2K in cancer have revealed some
vulnerabilities that may allow targeting of this pathway for therapeutic
benefit. Conflicting mechanistic data as to whether eEF2K promotes
or suppresses tumour growth expand this therapeutic potential
further, as the pathway could be susceptible to either activation or
suppression. The key goal now is to discover which tumour types, or
indeed subtypes, are susceptible to what mode of eEF2K targeting.
Dysregulation of eEF2 function and neurodegenerative disease
The role of eEF2 phosphorylation in the homeostatic brain is linked to
the Ca2+ sensitivity of eEF2K, which controls local protein synthesis
rates upon ion influx from neurotransmission (reviewed in Taha et al.,
2013; Delaidelli et al., 2019). Here, we focus on the role of this
pathway in neurodegeneration. Both eEF2 and eEF2K are expressed
within the axons, dendrites and soma of neurons and show
aberrant expression in neurodegenerative pathologies. eEF2K
mRNA expression is increased in Alzheimer’s disease (AD) brains,
and eEF2 phosphorylated T56 (T56-P) is heightened in the
hippocampus and cortex of AD patients, in close proximity to areas
of deposition of Tau. This protein is the main component of the
intracellular filamentous inclusions that result in AD-associated
proteotoxicity (Jan et al., 2017; Beckelman et al., 2019). Similarly, in
Parkinson’s disease (PD), eEF2K shows higher levels of
transcription, and eEF2 T56-P is increased in neurons within, but
not limited to, regions affected by the disease (Jan et al., 2018).
Importantly, mouse models of both AD and PD show increased
phosphorylation of eEF2 (Ma et al., 2014; Jan et al., 2018;
Beckelman et al., 2019). Genetic or pharmacological targeting of
eEF2K in AD or PD cultured neurons, Caenorhabditis elegans or
mouse models (Ma et al., 2014) restores normal electrophysiology
and even reverses disease-associated behavioural defects (Ma et al.,
2014; Jan et al., 2018; Jan et al., 2017). Interestingly, eEF2K
inhibition does not correlate with altered deposition of amyloid
plaques (Beckelman et al., 2019), but instead reduces reactive oxygen
species within cultured neurons and increases synapse formation (Jan
et al., 2018; Beckelman et al., 2019).
Modulation of eEF2K activity, in addition to its effects on global
protein synthesis rates, also selectively controls the expression of
subsets of neuroprotective proteins, although this is context dependent.
For example, heterozygous deletion of eEF2K in the Tg19959 AD
mouse model showed increased expression calbindin in the
hippocampi, which corresponded with neuroprotection (Beckelman
et al., 2019). However, in healthy neurons, phosphorylation of eEF2
and a decrease in elongation rates rapidly increased translation of
synaptic proteins with potentially neuroprotective functions such as
brain-derived neurotrophic factor (BDNF) and tripartite motif
containing 3 (TRIM3) in response to normal synaptic activity (Autry
et al., 2011; Heise et al., 2016; Verpelli et al., 2010).Moreover, inmice
with early-stage prion disease, cooling-associated suppression of
elongation via phosphorylation of eEF2K correlated with increased
expression of the synaptic protein reticulon 3 (RTN3), which was
shown to be neuroprotective (Bastide et al., 2017). RTN3
overexpression was mediated by the interaction of the corresponding
Table 1. eEF2K expression and patient prognoses in cancer
Cancer type
Expression
analysed
Prognosis
with
high eEF2K Reference
Colorectal cancer mRNA and
protein
Positive (Ng et al., 2019)
Triple-negative breast
cancer
Protein Negative (Bayraktar et al.,
2017, 2018)
Hormone-receptor-
positive breast cancer
Protein Negative (Meric-Bernstam
et al., 2012)
Lung cancer mRNA Negative (Bircan et al.,
2018)
Neuroblastoma mRNA Negative (Delaidelli et al.,
2017)
Medulloblastoma mRNA Negative (Leprivier et al.,
2013)
Glioblastoma multiforme mRNA Negative (Leprivier et al.,
2013)
The data show that the outcome is cancer-type specific.
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Rtn3 transcript with RNA-binding protein 3 (RBM3), which promoted
its recruitment to the ribosome, but was also driven by the decrease in
elongation rate (Bastide et al., 2017; Peretti et al., 2015).
But how does suppression of global translation elongation result in
enhanced expression of select transcripts? These can be explained in a
model in which the relative rates of the two steps of translation
elongation, decoding and translocation, govern specific gene
expression on a global scale (Bastide et al., 2017). Transcripts that
allow fast decoding due to their usage of highly abundant tRNAs are
more responsive to changes in the rate of translocation than transcripts
that are decoded more slowly. Thus, the slowest-decoded messages
escape suppression by slowing of translocation, whereas the faster-
decoded messages are repressed. eEF2 catalyses translocation, with
its phosphorylation slowing this step of elongation to make decoding
the limiting step across the majority of messages.RTN3 is decoded by
lower-abundance tRNAs,meaning that its expression is increased due
to insensitivity to suppressed translocation. It would be of interest to
assess the role of RNA-binding proteins, such as RBM3, and our
decoding/translocation rate model on the expression of additional
transcripts that are induced by eEF2K activation in neurons, such as
calbindin, BDNF and TRIM3 (Autry et al., 2011; Heise et al., 2016;
Verpelli et al., 2010).
eEF2 is of great interest in neuron biology and pathology, with
studies of its roles in neurodegenerative diseases helping to reveal
previously unappreciated mechanisms of gene expression control.
Extensive preclinical work presents eEF2K as an attractive
therapeutic target for both AD and PD, especially given the
viability of eEF2K knockout and kinase-impaired mice (Gildish
et al., 2012; Chu et al., 2014b), although these mice display reduced
female fertility at advanced age and impaired learning. However, the
importance of eEF2 phosphorylation in the normal brain has also
been documented (Autry et al., 2011; Heise et al., 2016), illustrating
the need for the cautious application of eEF2K inhibitors against
neurodegenerative diseases.
Additional factors that contribute to elongation rates
eIF5A
Although eIF5A was originally described as a translation initiation
factor (Benne and Hershey, 1978; Schreier et al., 1977; Kemper
et al., 1976), its role in translation elongation and termination
account for most of its activity (Schuller et al., 2017; Pelechano and
Alepuz, 2017). Humans have two isoforms of eIF5A – eIF5A1 and
eIF5A2 – that share 84% sequence similarity (Gordon et al., 1987),
with eIF5A1 being widely expressed and eIF5A2 only present in the
brain and testis (Jenkins et al., 2001; Clement et al., 2003). eIF5A is
the only protein to contain hypusine. Hypusination of eIF5A is a
two-step process through which deoxyhypusine synthase catalyses
the addition of an aminobutyl moiety from spermidine to the
ε-amino group of lysine 50 of eIF5A, resulting in the formation of
deoxyhypusine-eIF5A. Subsequently, deoxyhypusine hydroxylase
hydroxylates deoxyhypusine-eIF5A to form the mature hypusine-
eIF5A (Cooper et al., 1983; Park et al., 2010). This post-
translational modification of eIF5A is essential for its function
since lysine mutants lack activity (Cano et al., 2008).
eIF5A binds in the E-site of the ribosome and projects
the hypusine-containing domain towards the P-site where it binds
the CCA-end of the tRNA (Fig. 2) and allosterically assists in the
formation of certain peptide bonds, e.g. proline-proline, to prevent
ribosomal stalling on these motifs (Gutierrez et al., 2013; Schuller
et al., 2017; Saini et al., 2009). For example, in B cells, eIF5A is
required for the efficient elongation on poly-proline stretches of
transcription factor EB (TFEB) (Zhang et al., 2019). Several recent
studies have identified multiple other tripeptides that require eIF5A
function, including DDP, PDP and DNP and non-proline containing
tri-peptides such as RDK, DVG and DDG, revealing a broader role
of eIF5A in translation elongation (Schuller et al., 2017). In addition
to its function in elongation, a recent study has also shown that
eIF5A is important for start codon selection since depletion of this
protein leads to an increase in translation via upstream open-reading
frames (Manjuanth et al., 2019).
eIF5A has been associated with development and progression of
multiple types of cancer (Mathews and Hershey, 2015). Recent data,
which describe a role of this protein in the modulation of
mitochondrial function, apoptosis and autophagy, are consistent
with a pro-proliferative and pro-survival function (Puleston et al.,
2019; Zhang et al., 2019; Lubas et al., 2018). Taken together, these
data suggest that eIF5A could be a promising new target for the
development of drugs targeting specific subtypes of cancer.
Coding sequences
The mRNA sequence within coding regions influences both
elongation rates and mRNA stability. Studies in yeast and other
organisms have shown that mRNA stability is directly regulated by
elongation speed, with slow decoding being sensed by the decay
machinery, meaning that non-optimal codons confer higher instability
on mRNA sequences than optimal codons (Hanson et al., 2018;
Presnyak et al., 2015; Radhakrishnan et al., 2016). Similarly, recent
data have shown that this codon-dependent translational effect on
mRNA stability is conserved in human cells and depends on the
number of ribosomes translating a given mRNA (Narula et al., 2019;
Wu et al., 2019).
mRNA modification
Advances in studying the epitranscriptome have identified
modifications within mRNA coding regions that influence
translation efficiency (Arango et al., 2018; Dominissini et al.,
2012). Intriguingly, N4-acetylcytidine (ac4C) modification of
mRNAs primarily occurs within coding sequences and is strongly
enriched for cytidine within wobble positions. When compared to
unmodified cytidine, ac4C enhances thermal stability of Watson-
Crick base-pairing, therefore promoting correct decoding and
enhancing both translation and mRNA stability (Arango et al.,
2018). These observations raise the possibility that modifications
within the mRNA coding sequence represent an emerging gene
expression control mechanism at the level of translation.
Crosstalk between elongation and initiation of mRNA translation
Although initiation and elongation are considered to be distinct
processes, some lines of evidence suggest that inhibition of
elongation, which leads to ribosome pausing or stalling, feeds back
to inhibit initiation, thus linking the regulation of these two steps in
protein synthesis. First, codon-dependent ribosome movement
around the start codon affects translation initiation rates (Chu et al.,
2014a). Second, blocking hypusination and, thereby, the activity of
eIF5A results in a total loss of polysomes and a defect in translation
initiation, rather than only an elongation block (Mandal et al., 2013).
Third, the eIF2α kinase general control non-derepressible 2 (GCN2),
which inhibits the formation of the ternary complex, comprised
of eIF2, GTP and tRNAiMet, and required to bring the initiator
tRNA to the ribosome, is associated with the ribosome complex
known as the P-stalk. The P-stalk contains a GTPase-associated
centre in which eEF1A and eEF2 function, suggesting that GCN2
may be able to sense stalled ribosomes (Inglis et al., 2019), although
further experimentation is required to prove this hypothesis. Finally,
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new research in MEFs shows that hydrogen peroxide treatment
induces phosphorylation of eEF2, which, in turn, results in the
phosphorylation of eIF2α and inhibition of initiation (Sanchez et al.,
2019). Taken together, these data suggest a mechanism by which
acute inhibition of translation is initiated by blocking elongation,
either through eEF2 phosphorylation or reduced expression and
activity of eIF5A, whereas eIF2α phosphorylation is required to
maintain the longer-term suppression of protein synthesis.
Conclusions
Control of translation elongation is essential to maintain protein and
cellular homeostasis, and there is strong evidence demonstrating
that dysregulation of this process is associated with disease such as
cancer and neurodegenerative disorders, as discussed herein, but
also with cardiovascular disease (reviewed in Liu and Proud, 2016).
There are a number of stages at which elongation rates can be
manipulated to block disease progression. These include the
inhibition of enzymes that are required for tRNA modifications at
the wobble base U34, the selective targeting of specific ARSs,
interfering with eIF5A function through inhibition of hypusination
and modulating the activity of eEF2K. In particular, eEF2K is an
attractive target since it is not required for mammalian development
or maintenance of cell viability, suggesting that its inhibition may
not have deleterious effects in healthy tissue. Moreover, this protein
is very distinct from other mammalian kinases and thus it may be
amenable to inhibition by selective compounds that do not target
other protein kinases. However, while inhibition of eEF2K may be
therapeutically beneficial in blocking cancer cell survival and
restoring protein synthesis in AD, further studies are required to
define its role in different cancer types and at differing stages in
tumorigenesis to fully assess its utility as a therapeutic target in
oncology. Overall, defining new ways to modify elongation control
will lead to the development of new therapeutic targets, although
more detailed studies are required to fully understand the role of this
process in cell-type-specific regulation of protein synthesis.
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